Cargando…
Challenges for Drug Repurposing in the COVID-19 Pandemic Era
The coronavirus disease (COVID-19) pandemic has affected an estimated 16 million persons and caused 0.6 million deaths worldwide by September 2020. The pandemic has led to a rush to repurpose existing drugs, although the underlying evidence base is of variable quality. The improving knowledge of the...
Autores principales: | Sultana, Janet, Crisafulli, Salvatore, Gabbay, Flic, Lynn, Elizabeth, Shakir, Saad, Trifirò, Gianluca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677570/ https://www.ncbi.nlm.nih.gov/pubmed/33240091 http://dx.doi.org/10.3389/fphar.2020.588654 |
Ejemplares similares
-
The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience
por: Gozzo, Lucia, et al.
Publicado: (2020) -
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
por: Frega, Giorgio, et al.
Publicado: (2020) -
Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports
por: Sultana, Janet, et al.
Publicado: (2020) -
Traceability of Pediatric Antibiotic Purchasing Pathways in Italy: A Nationwide Real-World Drug Utilization Analysis
por: Sultana, Janet, et al.
Publicado: (2020) -
Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery
por: Li, Xinlei, et al.
Publicado: (2021)